3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
3
Unknown
1
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Conditions
Carcinoma, Renal Cell
14
Neoplasm Metastasis
6
Kidney Neoplasms
5
Breast Neoplasms
5
Carcinoma, Non-Small-Cell Lung
4
Glioblastoma
3
Urinary Bladder Neoplasms
2
Prostatic Neoplasms
2
Neoplasms
2
Uveal Melanoma
1
Urethral Neoplasms
1
Thyroid Neoplasms
1
Thymoma
1
Stomach Neoplasms
1
Sarcoma
1
Recurrence
1
Ovarian Neoplasms
1
Lung Neoplasms
1
Hormone Refractory Prostate Cancer
1
Glioma
1
Gastrointestinal Stromal Tumors
1
Gastrointestinal Neoplasms
1
Fatigue
1
Endometrial Neoplasms
1
Colorectal Neoplasms
1
Carcinoma
1
Carcinoid Tumor
1
Brain Neoplasms
1
Interventions
Cyclophosphamide
17
fludarabine
13
Dexamethasone
12
Cisplatin
11
Rituximab
10
Gemcitabine
9
Paclitaxel
7
Lenalidomide
7
Decitabine
7
Cytarabine
7
Bendamustine Hydrochloride
7
fludarabine phosphate
6
N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide
6
Etoposide
6
Carboplatin
6
Bortezomib
6
Radiotherapy
5
Injections
5
Azacitidine
5
camrelizumab
4
apatinib
4
Valproic Acid
4
Thalidomide
4
Procarbazine
4
Oxaliplatin
4
Drug Therapy
4
Antilymphocyte Serum
4
tislelizumab
3
pomalidomide
3
liposomal doxorubicin
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Unknown
×
Recurrence
×
Sunitinib
×
Clear all
NCT00535379
2010-08-30
SURGE01-07
Medical University Innsbruck
Phase 2
Unknown
70 enrolled